Novartis (NOVN) PT Set at CHF 84 by JPMorgan Chase & Co.

JPMorgan Chase & Co. set a CHF 84 target price on Novartis (VTX:NOVN) in a research note published on Wednesday. The brokerage currently has a neutral rating on the stock.

Several other brokerages have also commented on NOVN. Morgan Stanley set a CHF 92 price objective on shares of Novartis and gave the company a buy rating in a research report on Friday, December 1st. Deutsche Bank set a CHF 83.50 price objective on shares of Novartis and gave the company a neutral rating in a research report on Wednesday, November 8th. Bank of America set a CHF 87 price target on shares of Novartis and gave the stock a sell rating in a report on Wednesday, December 6th. Sanford C. Bernstein set a CHF 97 price target on shares of Novartis and gave the stock a buy rating in a report on Thursday, October 26th. Finally, Societe Generale set a CHF 95 price target on shares of Novartis and gave the stock a buy rating in a report on Wednesday, October 25th. Three investment analysts have rated the stock with a sell rating, six have issued a hold rating and seven have issued a buy rating to the company. Novartis has an average rating of Hold and a consensus price target of CHF 86.97.

Novartis (NOVN) opened at CHF 83.88 on Wednesday. The company has a market cap of $218,960.00 and a P/E ratio of 30.61. Novartis has a 1 year low of CHF 69.50 and a 1 year high of CHF 85.40.

TRADEMARK VIOLATION NOTICE: “Novartis (NOVN) PT Set at CHF 84 by JPMorgan Chase & Co.” was originally posted by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are accessing this piece of content on another site, it was copied illegally and republished in violation of United States & international copyright laws. The legal version of this piece of content can be read at https://www.dispatchtribunal.com/2018/01/14/novartis-novn-pt-set-at-chf-84-by-jpmorgan-chase-co.html.

About Novartis

Novan, Inc, a clinical-stage drug development company, focuses on the development and commercialization of nitric oxide-based therapies in dermatology. Its lead product candidate is SB204, a cosmetically elegant topical gel that targets multiple mechanisms of action for the treatment of acne vulgaris.

Analyst Recommendations for Novartis (VTX:NOVN)

Receive News & Ratings for Novartis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novartis and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply